- Clinical use of lixisenatide2014 | Second Faculty of Medicine
- Lixisenatide expands treatment of diabetes2015 | Second Faculty of Medicine
- Lixisenatide +12013 | Second Faculty of Medicine
- Lixisenatide - a novel prandial GLP-1 receptor agonist2013 | Second Faculty of Medicine
- Effect of the use of lixisenatide in antidiabetic therapy intensification2015 | First Faculty of Medicine
- Clinical experience with a combination of lixisenatide and oral antidiabetic drugs in the treatment of the type 2 diabetes mellitus2015 | Second Faculty of Medicine
- Clinical experience with combination lixisenatide PAD in therapy of type 2 diabetes2015 | Second Faculty of Medicine
- Lixisenatide/glargine - a novel fixed-ratio combination and its position in the treatment of type 2 diabetes2018 | First Faculty of Medicine
- Deintensification to a fixed mixture of insulin glargine and lixisenatide as a way to modern antidiabetic therapy in patients with type 2 diabetes mellitus2020 | First Faculty of Medicine
- New drugs in type 2 diabetes mellitus therapy2013 | Second Faculty of Medicine
- New possibilities in treatment of type 2 diabetes2012 | Second Faculty of Medicine
- Expert Opinion on the Therapeutic Use of the Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide: a Central/Eastern European Perspective2020 | First Faculty of Medicine
- Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis2023 | First Faculty of Medicine
- Porovnání klinické účinnosti liraglutidu oproti lixisenatidu u pacientů s diabetes mellitus 2. typu léčených metforminem - 26týdenní prospektivní randomizovaná studie LIRA-LIXI2016 | First Faculty of Medicine
- What are the likely effects of new large studies from 2015 on the therapy type-2 diabetes?2016 | Second Faculty of Medicine
- How will diabetes treatment change with new pharmaceuticals?2015 | Second Faculty of Medicine
- Inkretinová analoga2018 | First Faculty of Medicine
- Komentář ke studii (Uspořádání a výchozí charakteristiky účastníků kardiovaskulární studie REWIND s dulaglutidem)2018 | First Faculty of Medicine
- An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus2022 | First Faculty of Medicine
- Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes2016 | Second Faculty of Medicine
- Výsledky a praktické výstupy studie REWIND2019 | Publication without faculty affiliation
- Studie CANVAS: kardiovaskulární a renální efekty canagliflozinu2017 | First Faculty of Medicine
- The Effect of GLP-1 Receptor Agonists on Postprandial Lipaemia2022 | First Faculty of Medicine
- Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results2022 | First Faculty of Medicine